LC
CLVS

Lindbrook Capital’s Clovis Oncology, Inc. CLVS Stock Holding History

Lindbrook Capital’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-225
Closed -$1K – 2044
2021
Q2 		$1K Sell
225
-915
-80% -$5.36K ﹤0.01% 1878
2021
Q1 		$8K Hold
1,140
– – ﹤0.01% 1126
2020
Q4 		$5K Buy
1,140
+967
+559% +$4.89K ﹤0.01% 1221
2020
Q3 		$1K Sell
173
-414
-71% -$2.48K ﹤0.01% 1703
2020
Q2 		$4K Buy
+587
New +$4.45K ﹤0.01% 1217

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Lindbrook Capital's CLVS Position: Q3 2021 in Review

Lindbrook Capital sold out of Clovis Oncology, Inc. (CLVS) in Q3 2021, closing a stake of 225 shares — an estimated $1K sold.

Lindbrook Capital first reported a position in CLVS in Q2 2020 and held it in 5 quarters. The position peaked at $8K in Q1 2021. 157 funds tracked by Wall St. Rank hold CLVS as of Q3 2021.

  • Lindbrook Capital reported no remaining Clovis Oncology, Inc. position as of Q3 2021 after selling out during the quarter.
  • Lindbrook Capital sold 225 Clovis Oncology, Inc. shares in Q3 2021, an estimated $1K.
  • Lindbrook Capital first reported a position in Clovis Oncology, Inc. in Q2 2020 and held it in 5 quarters.
  • Lindbrook Capital's Clovis Oncology, Inc. position peaked at $8K in Q1 2021.
  • 157 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2021.

Based on Lindbrook Capital's 13F filing for Q3 2021, filed 5 Nov 2021.